cyrilzakka/clinical-trials huggingface dataset:
Anterior Shoulder Instability Treated with a Semitendinosus Subscapular Sling Procedure

The arthroscopic subscapular sling procedure is a new technique for shoulder stabilization, which has been developed in human cadaveric studies by Klungsøyr et al, but has yet to be tested clinically. The procedure stabilizes the shoulder by using a semitendinosus graft that makes a new labrum and a sling around the subscapular tendon. Extensive biomechanical robotic testing of the procedure shows significant less translation and thus better stability of the humeral head with the sling compared to a normal Bankart repair. The investigators consider the biomechanical results after robotic testing sufficient to advocate a planned pilot study in humans. In this pilot study the clinical and radiological results of the sling will be investigated in a small number of cases. The safety of the subscapular sling procedure will be assessed. This studies results are expected to be a further step towards implementation of the sling procedure as a surgical option for shoulder instability.


Eligibility Criteria:
Inclusion Criteria:

* Clinical anterior instability of the shoulder and/or previous failed Bankart repair or arthroscopic findings concluding with too weak anterior structures to perform capsulolabral or labrum repair
* Be able to understand oral and written Norwegian /English

Exclusion Criteria:

* Cuff injury or previous cuff repair
* Surgical fracture treatment of the glenoid or humeral head
* Other instability procedures in the shoulder except Bankart repair and anterior capsular plications
* Previous infections in the shoulder
* MRI detectable fatty infiltration of the subscapularis or partial/total tendon rupture
* Severe glenohumeral arthrosis
* Multidirectional or posterior instability
* Not able to comply fully with the protocol due to psychosocial and physical conditions
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer

This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients (only questionnaires) with bronchopulmonary cancer treated by Chemotherapy and/or Immunotherapy or Oral targeted therapy. The primary objective of the study is to evaluate the number of unscheduled consultations/hospitalizations during 6 months.

Currently, several treatments can be used for bronchopulmonary cancers: targeted oral therapy (OCT), oral chemotherapy, iv chemotherapy, iv immunotherapy. These therapies are rather unknown to community pharmacy and induce several adverse effects and drug interactions. These treatments require collaboration between different professionals (community and hospital pharmacists) in order to allow follow up and security in patient supportive care.

In our context of shortage of care staff, with a polymedicated and elderly population, we would like to assess the impact of hospital pharmacist in the drug management for patient with bronchopulmonary cancers treated by these therapies.

Other French studies (Lille, Angers, Tours) involving hospital pharmacists were carried out and aimed to evaluate the number of pharmaceutical interventions carried out without assessing the impact on the patient. In addition, no study concerns the Center Val de Loire region.

The aim of the study is to impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations.

This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients with bronchopulmonary cancer. Participants will be included after being informed and after obtaining no opposition to participate. Data collection sheet will be performed by hospital pharmacist at inclusion. Participants will be treated according to standard of care for cancer treatment. An interview will be performed 1 month, 3 months and 6 months after inclusion between hospital pharmacist and participant to obtain information's on cancer treatments (questionnaires). These interviews will be performed by phone or when the patient comes to the hospital for a follow-up consultation as part of the treatment of his cancer (standard of care).

A total of 60 participants will be included in this study based on 1) the number of patients received a novel cancer treatment in the center during 12 months and 2) considered eligibility criteria, pharmacist availability and patients consent.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female ≥ 18 years
2. Patient without cognitive impairments
3. Patient with bronchopulmonary cancer
4. Patient treated by chemotherapy, immunotherapy or oral targeted therapy

Exclusion Criteria:

1. Patient informed and opposed to participate
2. Language barrier and lack of translator
3. Patient under guardianship, curatorship or deprived of liberty
4. Pregnant or breastfeeding women
5. Participation in any drug clinical drug trials
6. Patient with no insurance
Effect of Large Language Model in Assisting Discharge Summary Notes Writing for Hospitalized Patients

This pilot study aims to assess the feasibility of carrying out a full-scale pragmatic, cluster-randomized controlled trial which will investigate whether discharge summary writing assisted by a large language model (LLM), called CURE (Checker for Unvalidated Response Errors), improves care delivery without adversely impacting patient outcomes.


Eligibility Criteria:
PATIENTS

Inclusion Criteria:

* Adult patients admitted to one of three participating cardiology services at Mayo Clinic in Rochester, MN

Exclusion Criteria:

* Minor patients (\<18)
* Patients admitted to a hospital service where CURE is not implemented

CLINICIANS

Inclusion Criteria:

* Clinicians who provide care to randomized patients included in this pilot

Exclusion Criteria:

* Clinicians who do not provide care to randomized patients included in this pilot
Cytopenias in Hospitalized Patients of Corona Virus Infection(COVID-19) During First and Other Waves

Demographic, Clinical and laboratory data as well as outcome of total 202 COVID-19 patients who were Polymerase Chain Reaction (PCR) positive and admitted in Fatima memorial Hospital, Lahore, Pakistan, was collected during first and other waves. Data of First wave is from May 2020 to July 2020, second wave from early November to Mid December 2020 and third wave from Mid march to June 2021. Investigator analyzed the data on basis of Systemic immune inflammatory index (SII) as well hematological parameters of First Wave were compared to other waves of COVID-19.


Eligibility Criteria:
Inclusion Criteria:

* COVID-19 Positive Hospitalized patients
* All genders

Exclusion Criteria:

* Patients with Known hematological disorders
* Patients with known chronic Liver Disease
Profiling Children and Youth With Cerebral Palsy in Relation to Feeding and Nutrition

HCPs will complete questionnaires about their patients with Cerebral Palsy (CP) and invite parents/caregivers of these patients to fill in questionnaires as well. Questionnaires include questions on individualized treatment, nutritional profile and management, and patient characteristics.

Coordinating health care professionals (HCPs; e.g. paediatric neurologists, physiotherapists) in different centres across different countries will be asked to participate in this cross-sectional study.

A) for the HCP to fill out a questionnaire about their CP child, related to general subject characteristics, motor function, co-morbidities, type of therapies, anthropometry, feeding mode and nutritional status; and B) for parents (/legal representatives) to receive and fill out questionnaires about their CP child and themselves, related to general subject characteristics, motor function, co-morbidities, type of therapies, anthropometry, feeding mode and nutritional status, participation and (their own) quality of life.

If parents (/legal representatives) agree to "A)", but not "B)" then a subject will still enter the study, but without the parental assessment.

Eligibility Criteria:
Inclusion Criteria:

1. Confirmed diagnosis of Cerebral Palsy
2. Age\<18 years
3. Have visited the HCP within the last year
4. Written informed consent provided by parents/legal representatives according to local law

Exclusion Criteria:

1. Neurodegenerative diseases
2. Acute infections: meningitis, encephalitis or poliomyelitis
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects

The purpose of this study is to compare the pharmacokinetics, safety, tolerability and immunogenicity of SB3 and Herceptin® (EU sourced Herceptin® and US sourced Herceptin®) in healthy male subjects.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects
* Have a body weight between 60.0 and 94.9 kg and a body mass index between 18.0 and 29.9 kg/m², inclusive.

Exclusion Criteria:

* history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological (including pancytopenia, aplastic anaemia or blood dyscrasia), pulmonary, neurologic, metabolic (including known diabetes mellitus), psychiatric or significant allergic disease excluding mild asymptomatic allergies.
* history of and/or current cardiac disease
* previously received any monoclonal antibody or fusion protein.
* history of cancer including lymphoma, leukaemia and skin cancer.
* Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) between Screening and the End of Study visit.
* intake medication with a half-life \> 24 h within 1 month or 10 half-lives of the medication prior to the administration of investigational product.
AS OCT Evaluation for Perforated Punctual Plugs

Evaluation of the perforated punctal plugs after implantation in cases of punctal stenosis regarding position and patency in the early postoperative period (during the first operative weak)

Prospective non randomized case series study included 50 eyes. The study is conducted on patients attending to the oculoplastic unit of ophthalmology department of Minia university hospital. Informed consents were obtained from the participants in this study. The study was adherent to the tenets of declaration of Heleniski.

Anterior segment optical coherence tomography(AS-OCT) was performed for the included patients after perforated plug implantation (during the first operative weak)

Eligibility Criteria:
Inclusion Criteria:

* Patients with punctal stenosis who will be treated by implantation of perorated punctal plugs

Exclusion Criteria:

* Patients who are not willing to participate in the study
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A).

The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label Sandostatin in patients who were "Non-Responders" in Study #D203 - FDA 102A; 2) To evaluate the efficacy and safety of Sandostatin during prolonged open-label treatment in "Responders" from Study #D03 - FDA 102A.


Eligibility Criteria:
Inclusion Criteria

Patients must have the following:

* Only patients who have completed the duration of Study D203, FDA 102A will be eligible for this study.
* Each of these patients must give written informed consent to participate in Study D204, FDA 102B as well.
A Multicenter Prospective Research on the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope

This study centers on the treatment of low pole renal stones by flexible ureteroscope and intends to find the key anatomical parameters using a prospective, randomized multi-center trial design and to make a more appropriate standard for flexible ureteroscopy of low pole renal stones.

With the development of manufacturing technique, new generation of flexible ureteroscopes have great initiative and passive bending capacity and have greatly expanded its application. In our clinical practice, we have found that IPA (Infundibulopelvic angle) is no longer a decisive factor for the success of f-URS（flexible ureteroscope） surgeries. Thus, we think it is necessary to have further study on the effect of anatomy of renal collecting system for f-URS surgeries.

Eligibility Criteria:
Inclusion Criteria:

* • Subject has provided informed consent and indicated a willingness to comply with study treatments

  * Subject is 18-70 yrs of age
  * Subject can be either male or female
  * Subject has a diagnosis of low pole renal stones according to CT urography(CTU) or intravenous pyelogram (IVP) results
  * Subject has a single stone 1\~2cm in size (KUB), or multiple stones 1\~2cm in cumulative size (KUB), and is a surgical candidate for the ureteroscopic approach

Exclusion Criteria:

* • Subject has an active urinary tract infection (e.g., cystitis, prostatitis, urethritis, etc.)

  * Subject has been diagnosed with a urethral stricture or bladder neck contracture
  * Subject has been diagnosed with a urinary tract infection related to stone obstruction within two weeks
  * Subject has severe hematuria that might blur the vision of the endoscopy
  * Subject is pregnant or in monthly period
  * Subject has coexistent disease like systemic disease, heart disease, lung disfunction or other diseases that could not tolerate the endoscopic surgery or anesthesia.
  * Subject has unadjusted diabetes or high blood pressure
  * Subject has a disorder of the coagulation cascade system that would put the subject at risk for intraoperative or postoperative bleeding
  * Subject is unable to discontinue anticoagulant and antiplatelet therapy preoperatively (2 weeks)
  * Subject has been diagnosed with hydronephrosis larger than 3cm according to the B-scan ultrasonography examination
  * Subject has any kind of anatomic abnormality of the urinary system that might have an influence on the surgery
A Study of MK-2060 in Healthy Participants (MK-2060-016)

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.


Eligibility Criteria:
Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

* Is in good health before randomization
* Has a body mass index (BMI) between ≥18 and ≤32 kg/m\^2, inclusive

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of cancer
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault

The goal of this study is to find the most effective and efficient version of the THRIVE app. The THRIVE app is the first app-based preventative intervention that has been found to reduce alcohol misuse and posttraumatic stress in people who have recently experienced sexual assault. In this trial, participants are randomly assigned to receive different versions of the THRIVE app to compare their impact. The THRIVE app is currently only available to participants in this study.


Eligibility Criteria:
Inclusion Criteria:

* Have reached the legal age of majority in their current state of residence
* Be able to read and speak English fluently
* Own a smartphone that cannot be accessed by others while the study app is installed, or they agree to take steps to reduce the risk that someone else will access the study app
* Be an enrolled undergraduate or graduate student at a recruitment site at the time of screening, or if they are on summer break, plan to be enrolled in the upcoming fall term
* Reside in the same state as the recruitment site for most of the year
* Have experienced a sexual assault (i.e., unwanted and non-consensual attempted/completed sexual contact) within the past 12 weeks at the time of screening
* Report ≥1 past-month heavy drinking episode (i.e., 5+ drinks on a given day or 15+ drinks in a given week for participants assigned male at birth and 4+ drinks on a given day or 8+ drinks in a given week for participants assigned female or intersex at birth) at the time of screening
* Endorse elevated posttraumatic stress symptoms at screening (defined as a score above a pre-established cut point on a screening measure of PTSD).

Exclusion Criteria:

* Active psychosis
* Location outside of the US at the time of screening
Common Sensing and Right Ventricular Automatic Capture (COGNATE)

This study will collect data on features for future pacemakers via an external non-implantable system.

COGNATE is an acute, confirmatory prospective, multi-center study designed to gather data on Brady and CRT-P indicated patients, with no restrictions on the type/brand of leads. This study will enroll up to 80 patients in up to 12 centers. Total duration of the study is expected to be 9 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are scheduled to receive either Pacemaker (dual chamber) or CRT-P devices based on physician discretion
* Patients who are willing and capable of participating in all testing associated with this Clinical Investigation
* Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria:

* Patient enrolled in any concurrent study, without Boston Scientific CRM written approval, that may confound the results of this study
* Patients with a prosthetic mechanical tricuspid heart valve
* Women who are pregnant
Innovative Toilet Seat Test for Patients With Symptoms of Constipation and/or Emptying Disorders

Emptying disorders are of the most common causes of constipation. An adjustable toilet seat was designed by " Shva-Nach" Ltd company, and is designed to facilitate the angle sitting position.

Its efficacy will be evaluated in the current study, on 50 volunteers who suffer from constipation and meet the Rome 3 criteria for constipation.

Emptying disorders are of the most common causes of constipation. Laxatives are usually unsuccessful. Behavioral therapy such as anorectal biofeedback , have a limited success in most hospitals in this country. Toilet seat that lifts the legs and brings us into a sitting position closer to squatting (which is the desired physiological position) can relieve these patients in the emptying process.

The Company " Shva-Nach" Ltd. and its design team designed a seat at an angle slightly elevated and a toilet stool customized to the personal anatomy of each subject.

The purpose of the study: evaluating efficacy elevated toilet seat with a support of a brackets stool making emptying easier in patients with constipation and difficulty in emptying.

Methods: An open, randomized, crossover study in use of a toilet seat and comparing it to a standard seat.

Eligibility Criteria:
Inclusion criteria:

1. Patients suffering from constipation and meet the criteria of Rome 3. No sub - distribution by emptying disorders or decreased stool frequency
2. Age group 18-80 years
3. Study population may include patients suffering from metabolic diseases such as diabetes mellitus, hypothyroidism and hypercalcemia.
4. Patients who understand the goals of the research and collaborate

Exclusion Criteria:

1. Patients who do not understand the goals of the research and / or unable to cooperate.
2. women with known pregnancy - second trimester and up
3. Patients with obesity - BMI\> 35 and / or weight over 120 kg
4. Neurological diseases - dementia, Parkinson's disease, CVA, multiple sclerosis, muscular dystrophy, spinal cord injury
5. Disabled patients on wheelchairs.
6. Patients with active anal fissure / fistula, active inflammation of the colon, patients after resection of the colon.
7. Minors and no judgment
Hepatic Histopathology in Urea Cycle Disorders

This is a multi-site, retrospective chart review as well as a prospective study to evaluate histopathologic findings in liver samples from individuals with any UCD diagnosis. This study will be conducted at all Urea Cycle Disorders Consortium (UCDC) sites: Baylor College of Medicine in Houston, TX and Children's National Medical Center in Washington D.C.

Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With early diagnosis and improved treatments, the survival of individuals with UCDs has improved, and this improved survival has led to unmasking of some long-term complications such as hepatic dysfunction and progressive fibrosis in a subset of patients. Hepatic complications in UCDs are quite variable and dependent upon the specific metabolic defect.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of primary urea cycle disorder based on clinical suspicion confirmed by enzyme activity, DNA testing or metabolite analysis.
* History of liver transplantation and/or liver biopsy OR
* Planned liver transplantation and/or liver biopsy

Exclusion Criteria:

* Unavailability of histopathology report from the liver biopsy or explant, or unavailability of liver tissue or slides from the biopsy or explant OR
* Anticipated inability to obtain pathology report, liver disease, tissue blocks, or pathology slides after liver biopsy or transplantation
* Known history of a secondary cause for liver disease such as chronic viral hepatitis, autoimmune liver disease, short gut, small bowel syndrome, alcohol liver disease, or TPN-related cholestatic disease
the Role of Repetitive Trans Cranial-magnetic Stimulation in Craving Reduction Among Opioid Use Disorder Patients

Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.

Administering high frequency rTMS to the left dorsolateral prefrontal cortex is possible to increase brain activity in the stimulated area and to change brain activity in associated regions that are part of the same neural circuit which may reduce craving.


Eligibility Criteria:
Inclusion Criteria:

1. Age range: 18-45 years old
2. Gender: males
3. Opioid Use disorder according to the DSM-5 (early abstinence starting 1 week up to 1 month).

Exclusion Criteria:

1. Presence of other serious mental illness (e.g.; psychotic disorders, bipolar affective disorder, depression with psychotic features).
2. Patients with any other serious medical illness.
3. Previous treatment with repetitive Trans- cranial magnetic stimulation.
4. Patients with contraindications to rTMS as cardiac patient with pacemaker.